BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Pfizer profit plunges 77% on generics competition, Exubera disaster]]>http://www.bloggingstocks.com/2007/10/18/pfizer-profit-plunges-77-on-generics-competition-exubera-disas/http://www.bloggingstocks.com/2007/10/18/pfizer-profit-plunges-77-on-generics-competition-exubera-disas/http://www.bloggingstocks.com/2007/10/18/pfizer-profit-plunges-77-on-generics-competition-exubera-disas/#commentsFiled under: , ,

Pfizer (NYSE: PFE) saw a sharp drop in its third-quarter profit, as the world's largest drugmaker's net income declined 77% for its most recently completed quarter. Two big takeaways here: Pfizer exited the Exubera inhaled-insulin product market (taking a $2.8 billion charge in the process) and the company faced more severe generic product competition as well.

Generic drugs always hamper big pharma firms, and it's not going to get any easier in the next few years. Pfizer even lowered its 2007 net income forecast when it released Q3 results, partly on expanded generic competition. Try this on for size: Pfizer's Q3 profit came in at $761 million, down from $3.36 billion in the year-ago quarter. Sales fell 2% in the quarter to come in at $12 billion.

In what could be considered a lack of due diligence (oddly) or some terrible mis-forecasting, Pfizer's purchase of the worldwide rights to the Exubera product from Europe's Sanofi-Aventis in 2006 was a complete disaster. The $1.4 billion purchase produced Q2 revenue for Pfizer of $4 million. Let's see: even nominal growth rates would have given Pfizer perhaps $20 million in global annual revenue. Yikes -- that's more than a 20-year period for return there. Pfizer called Exubera numbers "disappointing," but I would call them "totally disastrous." Adding to the pain are the exclusivity losses for blockbuster products like Zithromax, Zoloft and Norvasc, but at least Pfizer sees the writing on the wall, what with 10,000 layoffs and everything.

Pfizer profit plunges 77% on generics competition, Exubera disaster originally appeared on BloggingStocks on Thu, 18 Oct 2007 09:42:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments]]>CompetitionExuberagenericgeneric drugsGenericDrugsPFEPfizerpharmaceuticalsQuarterly earningsQuarterlyEarningsThu, 18 Oct 2007 09:42:00 EST<![CDATA[Novo Nordisk drug data a 'positive surprise']]>http://www.bloggingstocks.com/2007/06/21/novo-nordisk-drug-data-a-positive-surprise/http://www.bloggingstocks.com/2007/06/21/novo-nordisk-drug-data-a-positive-surprise/http://www.bloggingstocks.com/2007/06/21/novo-nordisk-drug-data-a-positive-surprise/#commentsFiled under: , ,

A press release [PDF] out this morning confirmed positive Phase III results of Novo Nordisk's (NYSE: NVO) potential blockbuster drug, Liraglutide, which is an analogue of the naturally-occurring hormone GLP-1 in development by Novo for the treatment of type 2 diabetes. The clinical results of the first of five late-stage studies showed that Liraglutide provided significantly better glucose control and led to significantly more weight loss than patients who used Sanofi-Aventis SA's (NYSE: SNY) Lantus.

Novo CEO Lars Rebien Sorensen said the company is looking to apply for regulatory approval of the drug in the U.S. and Europe in the middle of next year, and hopes to receive approval by mid-2009.

This data is excellent news for Novo, who has been trying to gain market share against competitors for some time in the attractive U.S. diabetes market. Unfortunately, the data is also a negative for rivals Amylin Pharmaceuticals Inc (NASDAQ: AMLN), Eli Lilly and Company (NYSE: LLY) and Pfizer Inc (NYSE: PFE), who all have diabetes drugs on the market - Byetta and the inhalable insulin Exubera, respectively.

Shares of Novo were up nearly 4.5% this morning on the Liraglutide data, which some analysts called "a positive surprise."

Novo Nordisk drug data a 'positive surprise' originally appeared on BloggingStocks on Thu, 21 Jun 2007 12:10:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments]]>AMLNAmylinAmylin PharmaceuticalsAmylinPharmaceuticalsblockbuster drugBlockbusterDrugByettaDiabetesEli LillyEliLillyExuberaLantusLiraglutideLLYNovoNovo NordiskNovoNordiskNVOPFEPfizerpositive clinical dataPositiveClinicalDataSanofiSanofi-AventisSNYThu, 21 Jun 2007 12:10:00 EST